Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17665810 | 0.97 | SLC18A3 (0.47) | SLC18A3PHGDHMGLLHTR6OPRM1 | |
| SCHEMBL29750851 | 0.88 | HRH3 (0.36) | SLC18A3ABCB1L3MBTL3L3MBTL1HRH3 | |
| SCHEMBL2115182 | 0.84 | SLC18A3 (0.35) | SLC18A3PHGDHMGLLOPRM1OPRL1 | |
| SCHEMBL16387906 | 0.83 | HRH3 (0.41) | SLC18A3HTR6ABCB1L3MBTL3L3MBTL1 | |
| SCHEMBL27376990 | 0.83 | DPP4 (0.38) | SLC18A3PHGDHMGLLOPRM1OPRL1 | |
| SCHEMBL2117622 | 0.83 | HRH3 (0.38) | SLC18A3OPRM1OPRL1POLBHSD17B10 | |
| SCHEMBL2115183 | 0.82 | PHGDH (0.35) | SLC18A3PHGDHMGLLOPRM1ABCB1 | |
| SCHEMBL20095585 | 0.81 | DPP4 (0.41) | SLC18A3PHGDHMGLLOPRM1OPRL1 | |
| SCHEMBL14529033 | 0.81 | L3MBTL1 (0.46) | L3MBTL3L3MBTL1MEN1KMT2AHRH3 | |
| SCHEMBL2117627 | 0.81 | HRH3 (0.37) | SLC18A3PHGDHMGLLOPRM1L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943080-A1 | LEVODOPA FORMULATIONS FOR RAPID RELIEF OF PARKINSON'S DISEASE | Civitas Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3831375-A1 | RAPID RELIEF OF MOTOR FLUCTUATIONS IN PARKINSON'S DISEASE | Civitas Therapeutics, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20110183974-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) | 2011-07-28 | — | — | US | disclosed |
| EP-2318400-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010013037-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183974-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | SHH, SMO, GLI1 | SLC18A3 4425/4885PHGDH 2329/4885MGLL 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.